干扰素-α治疗慢性乙型肝炎的疗效及其影响因素的研究(英文)

Study of Therapeutic Efficiency and Efficient Factor of Interferon for Chronic Hepatitis B

目的:分析影响干扰素-α(IFN-α)治疗慢性乙型肝炎(CHB)疗效的因素。方法:选择2006年到2009年青岛市传染病医院住院的CHB患者46例,应用IFN-α治疗48周,根据IFN-α治疗的疗效将其分为应答组与无应答组,评价患者的宿主、病毒载量及生化指标等因素对疗效的影响。结果:两组间的性别比例、年龄和病程无显著差异(P>0.05),应答组治疗前HBV-DNA载量低于无应答组,ALT水平高于无应答组,HBeAg阳性患者的应答率高于HBeAg阴性患者,差异均具有统计学意义(P<0.05),应答组在治疗12周时HBV-DNA载量下降>2log的比例高于无应答组,差异具有统计学意义(P<0.05)。结论:治疗前HBVDNA载量低、ALT水平高和HBeAg阳性以及治疗12周时的HBVDNA应答可以作为干扰素-α治疗慢性乙型肝炎48周时应答的预测因素。

Objective： To investigate the influencing factors of the efficacy of interferon α （IFN-α） on patients with chronic hep- atitis B （CHB）. Methods： 46 cases of CHB patients were chosen in this study, who were treated with IFN-α for 48 weeks in Qingdao Hospital for Infectious Diseases from January 2006 to June 2009, which were divided into responding group and non-responding group according to the efficacy of IFN-α. The influence of host factors, viral loads and biochemical factors on the efficacy of IFN-α was de- tected. Results： The proportions of sex and the mean ages and courses of disease were similar in the two groups （P 0.05）. The pre-treat- ment HBV-DNA loads were lower and the ALT levels were higher in responding group than those in non-responding group （P 0.05）, while the responding rate of the patients with HBeAg positive was higher than that with HBeAg negative （P 0.05）. The rate of HBV-DNA load decreased more than that of 2 log at the 12 weeks of treatment was significantly higher in the responding group than that in the non-responding group （P 0.05）. Conclusion： The lower HBV DNA load, higher ALT level and HBeAg positive before treatment and the response of HBV DNA at the week 12 of treatment may be the predicting factors of the response at week 48 of IFN-α treatment in the CHB patients.